Skip to main content
OpenTrials
Completed

NCT Number: NCT02306109

Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)

ErmoSLA is a multicentric, randomized, controlled trial to compare effects of an "intensive" or "standard" motor rehabilitation treatment on motor disability in people with ALS

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Neuroscience, S. Anna Hospital, Ferrara, Italy

Loading trial locations.

About this study

The study is a multicentric, randomized, controlled trial to compare effects of standard versus intensive motor rehabilitation treatment for people with ALS.

Eligible patients are going to be randomly assigned to the Standard or Intensive treatment (controlling for ALSFRSR rates at enrollment, age and site of onset). Randomization ratio is 1:1.

Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions. The program consists of exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions patient and caregiver are going to continue activity with supervision through regular follow up.

Intensive treatment is characterized by an increased volume of the above mentioned exercises: 5 sessions/week (45 minutes each one) for 10 weeks for a total of 50 sessions. At the end of the 50 sessions patient and caregiver are going to continue activity with supervision through regular follow up.

Collection and analysis of data

Recruitment: during the first 18 months of the study. Outcome measures: evaluated at T0-T3-T6-T9-T12-T15-T18-T21-T24. Rating scales will be administered by a neurologist in singe blind method with respect to the treatment.

Data collection will be done through an ad hoc Case Report Form and entered into a database on a dedicated website.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of possible, probable or definite ALS according to the Revised El Escorial Criteria
  • Time from diagnosis <18 months at screening.
  • Forced vital capacity (FVC)> 50% at screening
  • Written informed consent

Patients will be required to take the full dose of Riluzole, but not assuming Riluzole do not constitute a criterion for exclusion.

Exclusion criteria

  • Enrolment in any other clinical trial in the three months prior to screening
  • Tracheostomy or NIV for> 23h/day for 14 consecutive days at screening.
  • Diagnosis of severe neurodegenerative diseases in addition to the ALS
  • Diagnosis of severe heart disease, current neoplasia, any unstable medical condition that contraindicates an intensive rehabilitation treatment
  • State of pregnancy or breastfeeding
  • Residency outside Emilia-Romagna Region
  • Lack of multidisciplinary follow-up

Treatment and study plan

Standard motor rehabilitation treatment

Procedure

Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up

Intensive motor rehabilitation treatment

Procedure

Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up

Primary outcomes

  1. Change from Baseline in ALSFRS R

    Time frame: 12 months

Secondary outcomes

  1. Rate of complications related to the disease: pressure sores, hospitalizations, infections

    Time frame: 12 months

  2. Perceived quality of care

    Time frame: 12 months

  3. Tracheostomy free survival

    Time frame: 12 months

  4. Time to supporting procedures (NIV and PEG)

    Time frame: 12 months

  5. Respiratory function: measured by FVC

    Time frame: 12 months

  6. Quality of Life: measured by McGill and ALSAQ40 scales

    Time frame: 12 months

  7. Disease symptoms (fatigue) measured with FSS

    Time frame: 12 months

  8. Depression measured by Beck Inventory Scale

    Time frame: 12 months

Sponsors and collaborators

Lead sponsor

Azienda Unita' Sanitaria Locale Di Modena

Other

Collaborators

  • Azienda USL Reggio Emilia - IRCCS
  • Azienda Unità Sanitaria Locale Ferrara
  • S. Anna Hospital
  • University of Modena and Reggio Emilia

Registry information

Official study title

Effects of Motor Rehabilitation Treatment on Disability and Quality of Life in Amyotrophic Lateral Sclerosis (ALS).

Acronym: ermoSla

Important dates

Study start
2015
Primary completion
2017
Study completion
2018
First posted
Dec 3, 2014
Registry last updated
Aug 7, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.